Observation on long-term effects of percutaneous transluminal angioplasty in treating Budd-Chiari syndrome
10.3760/cma.j.issn.0254-1432.2010.010.002
- VernacularTitle:经皮腔内血管成形术治疗布-加综合征长期疗效观察
- Author:
Guohong HAN
;
Chuangye HE
;
Changjiang LIU
;
Zhanxin YIN
;
Jianhong WANG
;
Xingshun QI
;
Kaichun WU
;
Ke XU
;
Daiming FAN
- Publication Type:Journal Article
- Keywords:
Budd-Chiari Syndrome;
Fibrosis;
Angioplasty
- From:
Chinese Journal of Digestion
2010;30(10):725-728
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of percutaneous transluminal angioplasty (PTA) in treating Budd-Chiari syndrome (BCS) and to analyze the long-term follow-up results. Methods From October 1998 to May 2008,98 BCS patients (inferior vena cava obstruction,n = 34 ; hepatic vein obstruction, n = 22; combined obstruction, n = 42) who accepted PTA treatment successfully were investigated. The changes of clinical manifestations and liver function post-operation were observed; the long term survival rate was evaluated. Results Only two patients were complicated with transhepatic puncture tract bleeding, the prognosis was good after emergency operation. Sixty patients presented with low extremities edema, which was fully subsided after PTA.Of eighty-eight ascites patients, ascites disappeared in eighty patients after operation, and in the other eight patients combined with oral diuretic treatment post-operation. The median Rotterdam prognostic score of one month post-operation and the last follow-up time point was 0. 11 and 0. 09, significantly lowered than pre-operation (1.12). The difference was statistical significance (P=0. 000). At 1, 3, 5 years postoperative, the cumulative vessel patency rates were 96%, 94% and 94% respectively, and the cumulative survival rates were 94%, 91% and 87%. Conclusions Treating BCS with PTA has a high success rate, a good safety and a long-term survival rate.
